Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
September 19, 2024 08:00 ET
|
Evaxion Biotech
The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded dataset and includes an advanced protein prediction featureThe launch will expectedly...
Canada's Only Single-Dose Cholera Vaccine Available Nationwide
September 16, 2024 08:00 ET
|
Bavarian Nordic A/S
Bavarian Nordic announces availability of VAXCHORA, Canada's only single-dose cholera vaccine for travelers (age 2 to 64) to cholera-affected countries.
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
September 16, 2024 07:00 ET
|
Evaxion Biotech
11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate15 out of the 16 patients had a reduction of their tumors (target lesions)79% of EVX-01’s vaccine targets...
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
September 09, 2024 08:00 ET
|
Evaxion Biotech
Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate 15 out of the 16...
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
September 09, 2024 07:00 ET
|
Evaxion Biotech
New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteriaThe...
Infectious Disease Expert Kelly Warfield Named Sabin’s New R&D President
August 20, 2024 07:00 ET
|
Sabin Vaccine Institute
caption: Sabin Vaccine Institute Research & Development President Kelly Warfield WASHINGTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Virologist and vaccine development leader Kelly Warfield has...
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
August 19, 2024 17:10 ET
|
Emergent BioSolutions
Active engagement with the World Health Organization, U.S. government and other global health leaders on critical efforts to prevent mpox disease transmission50,000 doses of ACAM2000®, (Smallpox...
Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus Vaccine
July 15, 2024 10:29 ET
|
Sabin Vaccine Institute
Laboratory at Makerere University Walter Reed Project, where Sabin’s Phase 2 Sudan ebolavirus vaccine clinical trial begins this month. WASHINGTON, July 15, 2024 (GLOBE NEWSWIRE) -- Sabin Vaccine...
Misleading COVID-19 headlines from mainstream sources did more harm on Facebook than fake news
May 30, 2024 15:01 ET
|
MIT Sloan School of Management
Cambridge, MA, May 30, 2024 (GLOBE NEWSWIRE) -- Since the rollout of the COVID-19 vaccine in 2021, fake news on social media has been widely blamed for low vaccine uptake in the United States — but...
HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 09, 2024 16:05 ET
|
HilleVax, Inc.
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May ...